A share of Hercules Capital Inc. (NYSE:HTGC) closed at $11.45 per share on Thursday, down from $12.38 day before. While Hercules Capital Inc. has underperformed by -7.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HTGC fell by -29.92%, with highs and lows ranging from $18.90 […]
Hercules Capital is an attractive, 11.5% yielding, internally-managed BDC with a differentiated strategy and a track record of success. Here''s my take on HTGC.
As of Thursday, Hercules Capital Inc.’s (NYSE:HTGC) stock closed at $13.78, down from $14.07 the previous day. While Hercules Capital Inc. has underperformed by -2.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HTGC fell by -16.41%, with highs and lows ranging from $18.90 to $12.61, […]
Hercules Capital is a well-run lender to high-growth companies. Check out what makes HTGC stock a very interesting income play.
Hercules Capital has a rare mispriced bond issue with a YTM of 7%. Click here for a full explanation and investment analysis.
atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has announced that the company has entered into a term loan facility for up to $175 million with Hercules Capital, Inc. (NYSE: HTGC). Latham & Watkins LLP represents atai in the transaction with a team led […] The post Latham & Watkins Represents atai Life Sciences in Term Loan Facility for Up to $175 Million from Hercules Capital appeared first on Legal Desire .
Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI ) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc. (NYSE: HTGC ). The company expects the new non-dilutive financing facility, together with the total existing cash in hand, will provide cash runway until 2025 , as the flexible draw availability provides options to optimize liquidity and capital structure moving forward in ATAI’s developments. The Financial Results Total cash of $312.5 million for the period ended June 30, 2022, compared to $362.3 million as of December 31, 2021. The net decrease of almost $50 million was due to operating activities and additional investments in the platform companies, while receiving $1.9 million from the conversion of promissory notes and equity issuances. R&D expenses totaled $17.9 million and $33.4 million for the three and six months ended June 30, 2022 respectively, compared to $16.0 million and $21.6 million for the same periods in 2021.
atai Life Sciences (ATAI) entered into a term loan facility for up to $175M with Hercules Capital (HTGC)."While we continue to execute on our diversified pipeline of differentiated…
Hercules Capital’s portfolio performed well in 2Q22 and non-accruals remained at a very low level. See why HTGC stock could be a good hedge against rate hikes.
Hercules Capital is a well-run internally managed BDC with a strong track record of growth.
HTGC earnings call for the period ending June 30, 2022.
Hercules Capital, Inc. (NYSE:NYSE:HTGC) Q2 2022 Earnings Conference Call July 28, 2022, 05:00 PM ET Company Participants Michael Hara - IR and Corporate Communications Scott Bluestein - CEO…
Hercules Capital (HTGC) Q2 net investment income per share of $0.32, matching the consensus estimate, increased from $0.30 in Q1 and was unchanged from Q2 2021.Q2 total investment income…
Hercules Capital (HTGC): Q2 NII of $0.32 in-line.Total investment income of $72.12M (+3.7% Y/Y) misses by $0.29M.
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the second quarter ended June 30, 2022. The earnings release can be accessed at Hercules’ Investor Relations website at https://investor.htgc.com/f
Hercules Capital (NYSE: HTGC ) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here''s what investors need to know before the announcement. Analysts estimate that Hercules Capital will report an earnings per share (EPS) of $0.33. Hercules Capital bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
IVERIC bio Inc (NASDAQ: ISEE ) has entered into a debt financing facility with Hercules Capital Inc (NYSE: HTGC ) and Silicon Valley Bank, providing the company with a total borrowing capacity of up to $250 million in non-dilutive debt financing. "We are grateful to secure this non-dilutive financing as it further strengthens our balance sheet and provides financial flexibility as … Full story available on Benzinga.com
Hercules Capital declares $0.35 dividendHercules Capital declares $0.35 dividend
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a supplemental cash distribution of $0.15 per share. This supplemental cash distribution will be paid out of Hercules Capital
Gritstone bio (GRTS) on Thursday announced an $80M credit facility with Hercules Capital (HTGC) and Silicon Valley Bank.At closing, $20M was drawn with an additional $10M available…
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2022 financial results conference call for Thursday, July
Hercules Capital is below Wall Street''s average price target, and is selling at much lower earnings multiple. Why do we consider HTGC stock a long-term BUY? Find out.
Stock Analysts'' downgrades for Monday, June 20th: Aerie Pharmaceuticals was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Assurant was downgraded…
Columbia is uniquely positioned to weather economic storms based on 2008 performance. Read more to find out why COLM stock is a hold.
NEW YORK , June 6, 2022 /PRNewswire/ -- The " Outdoor Apparel Market by Distribution channel (Offline and Online) and Geography (APAC, Europe , MEA, North America , and South America ) - Forecast and Analysis 2020-2024 " report has been added to Technavio''s offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years. The potential growth difference for the outdoor apparel market between 2019 and 2024 is USD 3.90 billion , as per the latest market analysis report by Technavio. The report predicts the market to record an accelerating growth momentum at a CAGR of 5% during the projected period. To get the exact yearly growth variance and the Y-O-Y growth rate, Talk to our analyst . Key Market Dynamics: Market Driver: Product innovation leading to portfolio extensions and product premiumization are influencing the market growth positively during the forecast period. Manufacturers are extending their product lines to include apparel for all age groups and different types of outdoor activities.
Horrocks leads Columbia''s Pride resource group, which provides education, resources and camaraderie to employees.
Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), the largest and leading specialty financing provider to innovative venture, growth
Hercules Capital Inc (HTGC) shares closed today at 1.7% below its 52 week high of $17.54, giving the company a market cap of $1B. The stock is currently flat year-to-date, up 81.7% over the past 12 months, and up 106.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.4%. Trading Activity Trading volume this week was 15.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Financials industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date is the same as the peer average. The company's stock price performance over the past 12 months beats the peer average by 62.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 947.3% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
PALO ALTO, Calif.(BUSINESS WIRE)Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that effective July 1, 2021, Wade Loo was appointed to the Read More » Hercules Capital Announces the Appointment of Wade Loo to Its Board of Directors The post Hercules Capital Announces the Appointment of Wade Loo to Its Board of Directors appeared on Stocks News Feed .
Announcement of Periodic Review: Moody''s announces completion of a periodic review of ratings of Hercules Capital, Inc. Read the full article at Moody''s
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), will conduct its 2021 Annual Meeting of Stockholders by virtual meeting on Thursday, June 24, 2021 at 9:00 a.m. (Pacific Time). The proxy statement for the meeting was mailed separately on or about April 30, 2021 to shareholders of record as of April 23, 2021. 2021 Annual Meeting of Stockholders June 24, 2021 at 9:00 a.m. Pacific Time Virtual Meeting via Internet: www.virtualshareholdermeeting
- Principal Repayments Delayed At Least Until January 1, 2022 - Repayment Delay and Recent ATM Activity Extends Cash Runway Substantially Through the First Quarter of 2022 DUBLIN, Ireland…
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (Hercules or the Company), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its intent to fully redeem approximately $75.0 million (face value) in issued and outstanding aggregate principal amount of the Companys 5.25% Notes due 2025 (CUSIP No. 427
HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m. Concurrent to this financing, the company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC). The Series B round included new investors Huizenga Capital Management, Monashee Investment [] The post HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital appeared first on FinSMEs .
HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced that it has completed a Series B financing round for gross proceeds of $67.4 million.
Hercules Capital Inc shares closed today at 0.2% below its 52 week high of $17.39, giving the company a market cap of $1B. The stock is currently up 22.7% year-to-date, up 90.0% over the past 12 months, and up 102.7% over the past five years. This week, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 1.3%. Trading Activity Trading volume this week was 47.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Financials industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -2.2% The company's stock price performance over the past 12 months beats the peer average by 159.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -75.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates. This second tranche was made available in connection with the recent U.S. Food and Drug Administration (FDA) approval of FOTIVDA® (tivozanib). “With the additional $20 million now available to us from Hercules, AVEO is well positioned to
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Moody’s Investors Service, Inc. (“Moody’s”) has assigned Hercules an investment grade credit and corporate rating of Baa3 with a stable outlook. “We are very pleased th
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”) today announced the completed issuance of a private offering in aggregate principal amount of $50.0 million 4.55% Notes due March 2026 (the “March B Notes”). On November 4, 2020, the Company completed the initial issuance of $50.0 million 4.50% Notes due March 4, 2026, which were initially assigned a BBB+ rating by Kroll Bond Rating Agency. The March B Notes are unsecured and bear an interest r
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that members of the executive management team will be virtually participating at the following event for the financial community: 2021 RBC Capital Markets Global Financial C
Hercules Capital reported better-than-expected 4Q results driven by a rise in new debt and equity commitments. Shares of the specialty finance company rose … The post Hercules Capital Posts Better-Than-Expected 4Q Results; Shares Gain Pre-Market appeared first on Smarter Analyst .
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020. “Despite the unique challenges of 2020, Hercules was able to reach several new financial
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a supplemental cash distribution of $0.05 per share. This supplemental cash distribution will be paid out of Hercules Capital
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a fourth quarter 2020 cash distribution of $0.32 per share. The following shows the key dates of the fourth quarter 2020 distr
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2020 financial results conference call for Tuesday, February 23, 2021, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will r
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended and restated loan and security agreement (the “Loan Agreement”). Terms of the facility would remain otherwise unchanged from the Loan Agreement
Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.
SAN FRANCISCO--(BUSINESS WIRE)--SingleStore, The Database of NowTM, today announced $80 million in new funding and a partnership with advanced analytics leader SAS. Insight Partners led the Series E round, with participation from new financial investor Dell Technologies Capital and equity participation from Hercules Capital. Existing investors Accel, Anchorage, Glynn Capital, GV and Rev IV also participated. This round, which brings SingleStore’s total funding to $238 million, means the company
Udacity has raised $238 million in funding to date from investors including Bertelsmann, Andreessen Horowitz, Charles River Ventures, Drive Capital and Hercules Capital.
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”) today announced a private offering totaling $100.0 million in aggregate principal amount of $50.0 million 4.50% Notes due March 2026 (the “November Notes”) and $50.0 million 4.55% Notes due March 2026 (the “March Notes”). The November Notes are unsecured and bear an interest rate of 4.50% per year, payable semiannually and will mature on March 4, 2026, and may be redeemed in whole or in part at
- ← Previous
- 1
- 2
- Next →